Острая печёночная недостаточность у взрослых

С.П.  Лукашик; Игорь Александрович Карпов

doi:10.36488/cmac.2019.1.46-55

Острая печёночная недостаточность у взрослых

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(1):46-55

Лукашик С.П., Карпов И.А.

10.36488/cmac.2019.1.46-55

острая печёночная недостаточность поражение печени осложнения терапия

Раздел

Болезни и возбудители

Тип

Журнальная статья

Публикация

Клиническая микробиология и антимикробная химиотерапия. 2019; 21(1):46-55

Аннотация Авторы Литература PDF Статистика Репринты

Аннотация

В статье систематизирована информация об этиологии, эпидемиологии и клинических проявлениях острой печёночной недостаточности. Приведены статистические данные о частоте её встречаемости при разных нозологических формах, описаны наиболее часто развивающиеся осложнения, изложены основные подходы к терапии. Цель обзора — обобщить имеющиеся данные и улучшить осведомленность врачей об острой печёночной недостаточности.

Лукашик С.П.

Белорусский государственный медицинский университет, Минск, Республика Беларусь

Карпов Игорь Александрович

igorkarpov57@mail.ru

Белорусский государственный медицинский университет, Минск, Республика Беларусь

1. Lee W.M., Stravitz R.T., Larson A.M. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55(3):965-967. DOI: 10.1002/hep.25551
2. Eddy D.M. A Manual for Assessing Health Practices and Designing Practice Guidelines. Philadelphia: American College of Physicians, 1992.
3. Bernal W., Wendon J. Acute liver failure. New Engl J Med. 2013;369:2525-2534. DOI: 10.1056/NEJMra1208937
4. Lee W.M. Etiologies of acute liver failure. Semin Liver Dis. 2008;28(2):142-152. DOI: 10.1055/s-2008-1073114
5. Lee W.M., Squires R.H. Jr., Nyberg S.L., et al. Acute liver failure: Summary of a workshop. Hepatology. 2008;47(4):1401-1415. DOI: 10.1002/hep.22177
6. O’Grady J.G., Portmann B., Williams R. Fulminant hepatic failure. In: Diseases of the Liver, Schiff L, Schiff R (Eds), Lippincott, Philadelphia 1993.
7. Oketani M., Ido A., Tsubouchi H. Changing etiologies and outcomes of acute liver failure: A perspective from Japan. J Gastroenterol Hepatol. 2011;26(1):65-71. DOI: 10.1111/j.1440-1746.2010.06574.x
8. Bernal W., Auzinger G., Dhawan A., et al. Acute liver failure. Lancet. 2010;376:190-201. DOI: 10.1016/S0140-6736(10)60274-7
9. Schiodt F.V., Davern T.A., Shakil O., et al. Viral hepatitis-related acute liver failure. Am J Gastroenterol. 2003;98:448-453. DOI: 10.1111/j.15720241.2003.t01-1-07223.x
10. Manka P., Bechmann L.P., Coombes J.D. Hepatitis E virus infection as a possible cause of acute liver failure in Europe. Clin Gastroenterol Hepatol. 2015;13:1836-1842. DOI: 10.1016/j.cgh.2015.04.014
11. Canbay A., Jochum C., Bechmann L.P. Acute liver failure in a metropolitan area in Germany: a retrospective study (2002-2008). Z Gastroenterol. 2009;47:807-813. DOI: 10.1055/s-0028-1109058
12. Peters D.J., Greene W.H., Ruggiero F., et al. Herpes simplex induced fulminant hepatitis in adults: a call for empiric therapy. Dig Dis Sci. 2000;45:2399-2404. DOI: 10.1023/A:1005699210816
13. Ronan B.A., Agrwal N., Carey E.J., et al. Fulminant hepatitis due to human adenovirus. Infection. 2014;42(1):105-111. DOI: 10.1007/s15010-013-0527-7
14. Polson J., Lee M.W. AASLD Position Paper: The Management of Acute Liver Failure. Hepatology. 2005;36:1179-1197. DOI: 10.1002/hep.20703
15. Vaquero J., Chung C., Cahill M.E., et al. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis. 2003;23:259269. DOI: 10.1055/s-2003-42644
16. Alba L., Hay J.E., Angulo P., et al. Lactulose therapy in acute liver failure. J Hepatol. 2002;36:33A. DOI: 10.1016/S0168-8278(02)80097-6
17. Bernal W., Cross T.J., Auzinger G., et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol. 2009;50:306-313. DOI: 10.1016/j.jhep.2008.09.012
18. Craig D.G., Zafar S., Reid T.W., et al. The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose. Aliment Pharmacol Ther. 2012;35:1408-1415. DOI: 10.1111/j.1365-2036.2012.05102.x
19. McGregor A.H., More L.J., Simpson K.J., Harrison D.J. Liver death and regeneration in paracetamol toxicity. Hum Exp Toxicol. 2003;22:221227. DOI: 10.1191/0960327103ht325oa
20. Dechene A., Sowa J.P., Gieseler R.K., et al. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology. 2010;52:1008-1016. DOI: 10.1002/hep.23754
21. Bechmann L.P., Jochum C., Kocabayoglu P., et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol. 2010;53:639-647. DOI: 10.1016/j.jhep.2010.04.029
22. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512-521. DOI: 10.1053/j.gastro.2005.05.006
23. Carrascosa M.F., Salcines-Caviedes J.R., Lucena M.I., Andrade R.J. Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? J Hepatol. 2015;62:751-752. DOI: 10.1016/j.jhep.2014.11.019
24. Lucena M.I., Kaplowitz N., Hallal H., et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55:820-827. DOI: 10.1016/j.jhep.2010.12.041
25. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451455. DOI: 10.1053/jhep.2002.34857
26. Reuben A., Koch D.G., Lee W.M. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:20652076. DOI: 10.1002/hep.23937
27. Roales-Gomez V., Molero A.I., Perez-Amarilla I., et al. DRESS syndrome secondary to ibuprofen as a cause of hyperacute liver failure. Rev Esp Enferm Dig. 2014;106:482-486.
28. Bosdure E., Cano A., Roquelaure B., et al. Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure. Arch Pediatr. 2004;11:1073-1077. DOI: 10.1016/j.arcped.2004.05.018
29. Syn W.K., Naisbitt D.J., Holt A.P., Pirmohamed M., Mutimer D.J. Carbamazepine-induced acute liver failure as part of the DRESS syndrome. Int J Clin Pract. 2005;59:988-991. DOI: 10.1111/j.13685031.2005.00550.x
30. Kocaoglu C., Cilasun C., Solak E.S., Kurtipek G.S., Arslan S. Successful Treatment of antiepileptic drug-Induced DRESS syndrome with pulse methylprednisolone. Case Rep Pediatr. 2013;2013:928910. DOI: 10.1155/2013/928910
31. Devarbhavi H., Singh R., Patil M., et al. Outcome and determinants of mortality in 269 patients with combination antituberculosis druginduced liver injury. J Gastroenterol Hepatol. 2013;28:161-167. DOI: 10.1111/j.1440-1746.2012.07279.x
32. Wai C.T., Tan B.H., Chan C.L., et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007;27:465-474. DOI: 10.1111/j.1478-3231.2007.01461.x
33. Ramappa V., Aithal G.P. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013;3:3749. DOI: 10.1016/j.jceh.2012.12.001
34. Hosseinnezhad A., Vijayakrishnan R., Farmer M.J. Acute renal failure, thrombocytopenia, and elevated liver enzymes after concurrent abuse of alcohol and cocaine. Clin Pract. 2011;1:e35. DOI: 10.4081/cp.2011.e35
35. Nakamoto S., Kanda T., Nakaseko C., et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci. 2014;15:21455-21467. DOI: 10.3390/ijms151121455
36. Chang M.L., Liaw Y.F. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61:1407-1417. DOI: 10.1016/j.jhep.2014.08.033
37. Campos Franco J., Martinez Rey C., Perez Becerra E., Gonzalez Quintela A. Cocaine related fulminant liver failure. An Med Interna. 2002;19:365-367.
38. Lange-Brock N., Berg T., Muller A.R., et al. Acute liver failure following the use of ecstasy (MDMA). Z Gastroenterol. 2002;40:581-586. DOI: 10.1055/s-2002-33416
39. Kaufmann P. Mushroom poisonings: syndromic diagnosis and treatment. Wien Med Wochenschr. 2007;157:493-502. DOI: 10.1590/S180759322010000500006
40. Sherlock S. Diseases of the Liver and Biliary System, 12th edition. Ed By Dooley J., Look A.S.F., Burroughs A.K., Heathcote E.J., Wiley-Blackwell., 2011, 771р.
41. EASL Clinical Practice Guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671-685. DOI: 10.1016/j.jhep.2011.11.007
42. Roberts E.A., Schilsky M.L. AASLD Practice guidelines: A practice guideline on Wilson disease. Hepatology. 2003;37:1475-1492. DOI: 10.1053/jhep.2003.50252
43. Korman J.D., Volenberg I., Balko J., et al. Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology. 2008;48(4):1167-1174. DOI: 10.1002/hep.22446
44. Darwish M. S., Plessier A., Hernandez-Guerra M., et al. (European Network for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167. DOI: 10.7326/0003-4819-151-3-20090804000004
45. Amitrano L., Guardascione M.A., Ames P.R., et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol. 2003;72(2):75. DOI: 10.1002/ajh.10254
46. Fuhrmann V., Ager B., Zubkova A., et al. Hypoxic hepatitis – epidemiology, pathophysiologyand clinical management. Wien Klin. Wochenschr. 2010;122:129-139. DOI: 10.1007/s00508-0101357-6
47. Dalton T.A., Berry R.S. Hepatotoxicity associated with sustainedrelease niacin. Am J Med. 1992;93:102-104. DOI: 10.1016/00029343(92)90689-9
48. Silva M.O., Roth D., Reddy K.R., et al. Hepatic dysfunction accompanying acute cocaine intoxication. J. Hepatol. 1991;12:312315. DOI: 10.1016/0168-8278(91)90832-V
49. Kamijo Y., Soma K., Nishida M., et al. Acute liver failure following intravenous methamphetamine. Vet Hum Toxicol. 2002;44:216-217.
50. Hoffman B.J., Pate M.B., Marsh W.H., et al. Cardiomyopathy unrecognized as a cause of hepatic failure. J Clin Gastroenterol. 1990;12:306-309. DOI: 10.1097/00004836-199006000-00015
51. Hay J.E. Liver disease in pregnancy. A review. Hepatology. 2008;47:1067-1076. DOI: 10.1002/hep.22130
52. Rahman T.M., Wendon J. Severe hepatic dysfunction in pregnancy. QJM. 2002;95:343-357. DOI: 10.1093/qjmed/95.6.343
53. Lowenthal A., Tur-Kaspa R., Brower R.G. Acute liver failure complicating ductal breast carcinoma: two cases and literature review. Scand J Gastroenterol. 2003;38:1095-1096. DOI: 10.1080/00365520310005370
54. Montero J.L., Muntane J., de las Heras S., et al. Acute liver failure caused by hepatic melanoma infiltration. J. Hepatol. 2002;37:540-541. DOI: 10.1016/S0168-8278(02)00219-2
55. Agarwal K., Jones D.E., Burt A.D., et al. Metastatic breast carcinoma presenting as acute liver failure and portal hypertension. Am J Gastroenterol. 2002;97:750-751. DOI: 10.1111/j.15720241.2002.05559.x
56. Borregaard L., Lyngsoe B.K., Fenger-Eriksen C., Gronbaek H., Brandsborg B. Acute liver failure following heat stroke after participating in a running event. Ugeskr Laeger. 2014;176:V01130075.
57. Jenniskens M., Langouche L., Vanwijngaerden Y.M., Mesotten D., Van den Berghe G. Cholestatic liver (dys)function during sepsis and other critical illnesses. Intensive Care Med. 2016;42:16-27. DOI: 10.1007/s00134-015-4054-0
58. Price B., Lines J., Lewis D., Holland N. Haemophagocytic lymphohistiocytosis: A fulminant syndrome associated with multiorgan failure and high mortality that frequently masquerades as sepsis and shock. S Afr Med J. 2014;104:401-406. DOI: 10.7196/samj.7810
59. Somasundaram A., Loganathan N., Varghese J., Shivakumar S., Jayanthi V. Does leptospirosis behave adversely in cirrhosis of the liver? Indian J Gastroenterol. 2014;33:512-516. DOI: 10.1007/s12664-014-0500-0
60. Berry P.A., Bernal W., Pagliuca A., et al. Multiple organ failure and severe bone marrow dysfunction in two 18 year-old Caucasian patients: Epstein-Barr virus and the haemophagocytic syndrome. Anaesthesia. 2008;63:1249-1254. DOI: 10.1111/j.1365-2044.2008.05584.x
61. Maharaj R., Pingitore A., Menon K., et al. MDMA-induced acute liver failure and transient abdominal pneumatosis. Am J Gastroenterol. 2015;110:963. DOI: 10.1038/ajg.2014.399
62. Peron J.M., Dalton H.R., Izopet J., Kamar N. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin? J Hepatol. 2011;54:1323-1324, [Author reply 13241325]. DOI: 10.1016/j.jhep.2011.01.009
63. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68:1256-1271. DOI: 10.1016/j.jhep.2018.03.005
64. Yu J.W., Sun L.J., Zhao Y.H., et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;55:775-783. DOI: 10.1007/s10620-009-1060-5
65. Tillmann H.L., Hadem J., Leifeld L. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256-263. DOI: 10.1111/j.13652893.2005.00695.x
66. Miyake Y., Iwasaki Y., Takaki A. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med. 2008;47:1293-1299. DOI: 10.2169/internalmedicine.47.10
67. Yu J.W., Sun L.J., Yan B.Z., et al. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int. 2011;31(4):499506. DOI: 10.1111/j.1478-3231.2011.02450.x
68. Jochum C., Gieseler R.K., Gawlista I. Hepatitis B associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009;80:235-240. DOI: 10.1159/000236009
69. Casals-Seoane F., Arberas-Díez B., García-Buey L. Tenofovir treatment of the severe acute hepatitis B. Rev Esp Enferm Dig. 2013;105(1):57-58. DOI: 10.4321/s1130-01082013000100015
70. Lisotti A., Eusebi L.H., Festi D., et al. Treatment with telbivudine for fulminant hepatitis B. J Dig Dis. 2013;14(11):619-621. DOI: 10.1111/1751-2980.12067
71. Sato R.L., Wong J.J., Sumida S.M. Efficacy of superactivated charcoal administration late (3 hours) after acetaminophen overdose. Am J Emerg Med. 2003;21:189-191. DOI: 10.1016/S0735-6757(02)42251-6
72. Keays R., Harrison P.M., Wendon J.A. A prospective controlled trial of intravenous N-acetylcysteine in paracetamol-induced fulminant hepatic failure. BMJ. 1991;303:1024-1029. DOI: 10.1136/bmj.303.6809.1026
73. Lee W.M., Hynan L.S., Rossaro L., et al. Acute Liver Failure Study Group. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;37(3):856. DOI: 10.1053/j.gastro.2009.06.006
74. Rengstorff D.S., Osorio R.W., Bonacini M. Recovery from severe hepatitis caused by mushroom poisoning without liver transplantation. Clin Gastroenterol Hepatol. 2003;1:392-396. DOI: 10.1053/S15423565(03)00179-4
75. Hruby K., Csomos G., Fuhrmann M. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Human Toxicol. 1983;2:183-195. DOI: 10.1177/096032718300200203
76. Montanini S., Sinardi D., Pratico C. Use of acetylsysteine as the lifesaving antidote in Amanita phalloides (death cap) poisoning. Case report on 11 patients. Arzneimittelforschung. 1999;49:1044-1047.
77. Acharya S.K., Bhatia V., Sreenivas V., et al. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebocontrolled study. Gastroenterology. 2009;136:2159-2168. DOI: 10.1053/j.gastro.2009.02.050
78. Durward Q.J., Amacher A.L., Del Maestro R.F., et al. Cerebral and cardiovascular responses to changes in head elevation in patients with intracranial hypertension. J. Neurosurg. 1983;59:938. DOI: 10.3171/jns.1983.59.6.0938
79. Ellis A.J., Wendon J.A., Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology. 2000;32(3):536-541. DOI: 10.1053/jhep.2000.9775
80. Bhatia V., Batra Y., Acharya S.K. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure – a controlled clinical trial. J Hepatol. 2004;41:89-96. DOI: 10.1016/j.jhep.2004.03.017
81. Nielsen H.B., Tofteng F., Wang L.P. Cerebral oxygenation determined by near-infrared spectrophotometry in patients with fulminant hepatic failure. J Hepatol. 2003;38:188-192. DOI: 10.1016/S01688278(02)00377-X
82. Strauss G., Christiansen M., Moller K., et al. S-100b and neuronspecific enolase in patients with fulminant hepatic failure. Liver Transpl. 2001;7:964-970. DOI: 10.1053/jlts.2001.28742
83. Tofteng F., Jorgensen L., Hansen B.A., et al. Cerebral microdialysis in patients with fulminant hepatic failure. Hepatology. 2002;36:13331340. DOI: 10.1053/jhep.2002.36944
84. Larsen F.S., Hansen B.A., Ejlersen E., et al. Cerebral blood flow, oxygen metabolism and transcranial doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Eur J Gastroenterol Hepatol. 1996;8:261-265. DOI: 10.1097/00042737-199603000-00014
85. McCashland T.M., Shaw B.W., Tape E. The American experience with transplantation for acute liver failure. Semin Liver Dis. 1996;16:427433. DOI: 10.1055/s-2007-1007255
86. Davies M.H., Mutimer D., Lowes J., et al. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet. 1994;343:13291330. DOI: 10.1016/S0140-6736(94)92471-6
87. Blei A.T., Olafsson S., Webster S., et al. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet. 1993;341:157158. DOI: 10.1016/0140-6736(93)90016-A
88. Shami V.M., Caldwell S.H., Hespenheide E.E., et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138-143. DOI: 10.1053/jlts.2003.50017
89. Nath F., Galbraith S. The effect of mannitol on cerebral white matter water content. J Neurosurg. 1986;65:41-43. DOI: 10.3171/jns.1986.65.1.0041
90. Strauss G., Hansen B.A., Knudsen G.M., et al. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol. 1998;28:199-203. DOI: 10.1016/0168-8278(88)80006-0
91. Ellis A., Wendon J. Circulatory, respiratory, cerebral and renal derangements in acute liver failure: Pathophysiology and management. Semin Liver Dis. 1996;16:379-387. DOI: 10.1055/s-2007-1007251
92. Forbes A., Alexander G.J., O’Grady J.G., et al. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology. 1989;10;306-310. DOI: 10.1002/hep.1840100309
93. Rakela J., Mosley J.W., Edwards V.M., et al. A double-blind randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci. 1991;36:1223-1228. DOI: 10.1007/bf01307513
94. Chatauret N., Rose C., Therien G., et al. Mild hypothermia prevents cerebral edema and CSF lactate accumulation in acute liver failure. Metab Brain Dis. 2001;16:95-102. DOI: 10.1023/A:1011622830569
95. Rose C., Michalak A., Pannunzio M., et al. Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. Hepatology. 2000;31:872-877. DOI: 10.1053/he.2000.5923
96. Jalan R., Damink S., Deutz N.E. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation. 2003;75:2034-2039. DOI: 10.1097/01.TP.0000066240.42113.FF
97. Schubert A. Side effects of mild hypothermia. J Neurosurg Anesthesiol. 1995;7:139-147. DOI: 10.1097/00008506-199504000-00021
98. Rolando N., Gimson A., Wade J., et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology. 1993;17:196-201. DOI: 10.1002/hep.1840170206
99. Karvellas C.J., Cavazos J, Battenhouse H., et al. US Acute Liver Failure Study Group Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2014;12(11):1942. DOI: 10.1016/j.cgh.2014.03.011
100. Heckman K.D., Weiner G.J., Davis C.S., et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult leukemia; 10,000/mm3 versus 20,000/mm3. J Clin Oncol. 1997.15:1143-1149. DOI: 10.1200/JCO.1997.15.3.1143
101. Munoz S.J., Stravitz R.T., Gabriel D. Coagulopathy of acute liver failure. Clin Liver Dis. 2009;13:95-107. DOI: 10.1016/j.cld.2008.10.001
102. Drews R., Weinberger S. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med. 2000;162:347-351. DOI: 10.1164/ajrccm.162.2.ncc3-00
103. Gazzard B.G., Henderson J.M., Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut. 1975;16(8):617-620. DOI: 10.1136/gut.16.8.617
104. Cobden I., Record C.O., Ward M.K. Paracetamol-induced acute renal failure in the absence of fuminant liver damage. BMJ. 1982;284:21-22. DOI: 10.1136/bmj.284.6314.505-d
105. Jain S., Pendyala P., Varma S., et al. Effect of renal dysfunction in fulminant hepatic failure. Trop Gastroenterol. 2000;21(3):118-120.
106. Ruiz-Santana S., Ortiz E., Gonzales B., et al. Stress-induced gastrointestinal lesions and total parenteral nutrition in critically ill patients: Frequency, complications, and the value of prophylactic treatment. A prospective, randomized study. Crit. Care Med. 1991;19:887-891. DOI: 10.1097/00003246-199107000-00011
107. Martin L.F., Booth F.V.M., Reines D., et al. Stress ulcers and organ failure in intubated patients in surgical intensive care units. Ann Surg. 1992;215:332-337. DOI: 10.1097/00000658-199204000-00005

Просмотров

0 Аннотация

0 PDF

0 Цитирования

Острая печёночная недостаточность у взрослых

Аннотация

Просмотров

Поделились

Процитировали Crossref